跳至主要内容
临床试验/NCT07048847
NCT07048847已完成不适用

The Effect of Supervised Aerobic Exercise on Adipokine and Myokine Biomarkers in Patients With Cancer During Systemic Chemotherapy

Izmir Bakircay University1 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2022年9月15日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
32
试验地点
1
主要终点
Irisin

研究概览

简要总结

This study is a single-blinded, prospective, controlled trial aiming to evaluate the effect of supervised aerobic exercise on adipokine and myokine biomarkers in patients with breast or colon cancer during their systemic chemotherapy.

详细描述

To determine the effect of aerobic exercise on adipokine and myokine biomarkers such as Interleukin-6 (IL-6), Irisin, Leptin and Adiponectin in the blood of breast or colon cancer patients receiving chemotherapy compared to ones who did not exercise during their systemic chemotherapy.

Patients who were diagnosed with solid type of cancer specifically focusing on breast or colon cancer will be recruited either to the exercise group (EG) or control group (CG) during their systemic chemotherapy. An individualized supervised resistive aerobic exercise which will be performed via stationary resistive biycle ergometer will be implemented along with the chemotherapy process for EG.

Each exercise session will be performed 2 times per week for at least 12 weeks (can be extended up to 24 weeks) during chemotherapy.

Exercise intensity will be set as submaximal, 50-70% of heart rate reserve, and each session will be lasted 35 minutes.

All exercise sessions will be supervised by the researchers to avoid potential side effects.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Having been diagnosed with solid type of cancer
  • •Being candidate for systemic chemotherapy
  • •Being volunteer to participate in an exercise program
  • •Aged between 18-70 years old

排除标准

  • •Having 2 or above grades according to the Eastern Cooperative Oncology Group (ECOG) performance status
  • •Having mental and/or cognitive deficits
  • •Ongoing medical and/or surgical (if any) complications
  • •Having neurological/orthopedical and/or severe respiratory dysfunctions
  • •Having any condition which corresponds to the contraindication of exercise (i.e. advanced stages, distant metastasis, infection)
  • •Having unstable vital parameters or having regularly used pharmacological interventions

结局指标

主要结局

Irisin

时间窗: From completion of systemic chemotherapy up to one week

Measuring Serum levels of Irisin via ELISA

Adiponectin

时间窗: From completion of systemic chemotherapy up to one week

Measuring Serum levels of Adiponectin via ELISA

Leptin

时间窗: From completion of systemic chemotherapy up to one week

Measuring Serum levels of Leptin via ELISA

Interleukin-6 (IL-6)

时间窗: From completion of systemic chemotherapy up to one week

Measuring Serum levels of IL-6 via ELISA

次要结局

未报告次要终点

研究者

发起方
Izmir Bakircay University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Alper Tuğral

Project Coordinator

Izmir Bakircay University

研究点 (1)

Loading locations...

相似试验